Effect of Vosoritide Therapy on IGF-I and Endogenous C-Type Natriuretic Peptide in Hypochondroplasia

What Was Tested

Researchers studied CNP (C-Type Natriuretic Peptide) and Vosoritide in this phase 2 clinical trial publication.

The researchers hypothesized that IGF-1 and CNP will be inversely associated at baseline and will respond differentially during a single-arm, unblinded, standardized 12-month phase 2 clinical trial of vosoritide in prepubertal patients aged 3 to 11 years with HCH and height less than -2.25 SD.

Anthropometrics, IGF-1, and NTproCNP were measured every 6 months.

Longitudinal changes in IGF-1 and NTproCNP as well as the correlations between these 2 analytes and changes in height SD and AGV were analyzed.

Why It Was Studied

Insulin-like growth factor-1 (IGF-1) and C-type natriuretic peptide (CNP) promote endochondral bone growth.

Who Took Part

PubMed indexes the participants as young children and children, both men and women.

What Was Measured

PubMed files the paper under topics including Insulin-Like Growth Factor I, Natriuretic Peptide, C-Type, Dwarfism, Lordosis, Limb Deformities, Congenital, Bone and Bones and Body Height.

Author keywords: C-type natriuretic peptide, IGF-1, NTproCNP, hypochondroplasia and vosoritide.

What This Means in Plain Language

This is a phase 2 clinical trial of CNP (C-Type Natriuretic Peptide) and Vosoritide.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the CNP (C-Type Natriuretic Peptide) compound page and the Vosoritide compound page, all human trials.